
Loading, please wait...

Loading, please wait...

Recognizing early psychological vulnerability in younger patients poses unique diagnostic challenges for pediatric psychiatrists and primary physicians. Recent longitudinal research offers essential clarity regarding clinical high risk psychosis during childhood and adolescence. Specifically, clinicians must understand how developmental stage and biological sex intersect to influence psychiatric presentations and disease progression over time.
Historically, psychiatric investigations focused predominantly on young adult cohorts to characterize the psychosis prodrome. Consequently, clinicians possessed limited developmental data regarding children and early adolescents who present with attenuated psychotic symptoms. To bridge this significant knowledge gap, researchers conducted a comprehensive naturalistic cohort study evaluating 221 individuals at clinical high risk alongside 159 healthy controls. The investigation meticulously monitored participants across an 18-month observational follow-up period. Moreover, the research team examined detailed sociodemographic profiles, global psychosocial functioning, mood alterations, and positive psychotic symptoms. In doing so, investigators sought to determine whether biological sex shapes early risk manifestations in youth. Initial pairwise comparisons indicated apparent sex differences in positive symptom intensity. However, comprehensive regression models accounting for healthy controls demonstrated that core high-risk symptoms did not inherently differ by sex. Therefore, these critical results suggest that baseline attenuated psychotic phenomena manifest similarly across boys and girls during childhood and adolescence. This finding challenges earlier assumptions derived primarily from adult literature.
Although attenuated psychotic symptoms showed comparable distributions between sexes, researchers observed distinct interactive patterns regarding affective comorbidity. Specifically, the statistical interaction between biological sex and diagnostic group significantly predicted depressive symptom burden. Adolescent females at clinical high risk exhibited substantially higher levels of depressive distress compared to their male peers. In addition, lifetime caffeine consumption showed a notable sex-by-group interaction, reflecting subtle behavioral and lifestyle differences among young individuals seeking mental health support. Clinicians frequently encounter severe internalizing symptoms in adolescent girls, which can easily overshadow or complicate subtle perceptual changes. Furthermore, concurrent depressive episodes frequently reduce cognitive resilience and amplify subjective distress in vulnerable adolescents. Because mood disorders and psychosis spectrum vulnerabilities regularly co-occur, practitioners must avoid viewing these presentations through isolated diagnostic categories. Instead, clinicians should carefully screen young female patients presenting with affective decline for emerging psychotic spectrum experiences. Recognizing these affective comorbidity profiles early empowers medical teams to tailor supportive psychotherapeutic interventions appropriately.
The longitudinal follow-up provided striking insights into clinical trajectories and symptom resolution. Most notably, multivariable regression revealed a significant interaction between participant age and biological sex regarding symptom remission at 18 months. Specifically, older adolescent females demonstrated a significantly higher probability of non-remission of their high-risk state compared to males. Interestingly, however, biological sex did not directly dictate conversion rates to full-threshold psychotic disorders during the study timeframe. Therefore, non-remission in older adolescent females did not simply reflect an accelerated transition toward schizophrenia spectrum disorders. Rather, this finding underscores persistent, subthreshold distress and protracted functional impairment among teenage girls. Moreover, persistent attenuated symptoms often impair academic engagement, interpersonal relationships, and family dynamics. Clinicians must recognize that a failure to achieve symptom remission represents a meaningful clinical outcome demanding ongoing therapeutic attention. Consequently, long-term monitoring remains essential for older adolescent girls, even when overt psychotic conversion does not materialize.
Why do older adolescent females experience greater difficulty achieving symptom remission? Developmental epidemiology demonstrates that psychosis-like experiences frequently occur throughout the general adolescent population, particularly among older teenage females. Furthermore, fluctuating gonadal hormones, neurodevelopmental reorganization, and unique sociocultural stressors converge during mid-to-late adolescence to amplify perceptual sensitivity. Consequently, many transient perceptual aberrations or unusual beliefs in girls may reflect heightened developmental distress rather than an unyielding psychotic prodrome. In contrast, young males often exhibit earlier onsets of primary psychotic disorders with prominent negative symptoms and cognitive deficits. Furthermore, social evaluative stress, relational peer conflicts, and emerging identity challenges disproportionately affect adolescent females during high school years. These cumulative pressures can sustain subthreshold psychological distress over extended periods. Therefore, clinicians must contextualize clinical ratings within normative developmental psychopathology. Disentangling true prodromal deterioration from puberty-related distress requires careful longitudinal observation rather than hasty diagnostic labeling.
The compelling findings from this landmark cohort encourage practitioners to reconsider how current diagnostic frameworks apply to children. Existing clinical high risk criteria were developed and validated primarily within older adolescent and adult cohorts. Consequently, applying these strict adult criteria to pediatric cohorts often introduces significant diagnostic noise and interpretive ambiguity. Moreover, standard psychometric instruments frequently fail to capture developmental nuances unique to childhood maturation and adolescent identity formation. Because older adolescent females report high rates of non-remitting symptoms without higher conversion, conventional criteria risk generating false-positive risk designations. Thus, psychiatric researchers advocate for recalibrating assessment thresholds to incorporate a clear developmental and sex-informed perspective. Additionally, clinical assessments should integrate cognitive evaluations, family psychiatric history, and objective functional measures rather than relying solely on self-reported perceptual anomalies. By refining diagnostic precision, clinicians can prevent unwarranted stigma while providing targeted support to genuinely vulnerable youth.
These empirical insights carry profound practical significance for child psychiatrists, pediatricians, and primary care physicians. First, healthcare providers must adopt a nuanced, holistic approach when assessing adolescents with suspected psychosis risk. Specifically, clinicians should conduct thorough evaluations that simultaneously examine mood instability, anxiety, academic performance, and peer relationships. Furthermore, when treating older adolescent females with persistent attenuated symptoms, clinicians should prioritize evidence-based psychotherapies, such as cognitive-behavioral therapy for youth. Providers should generally avoid prematurely prescribing antipsychotic medications in the absence of rapid functional collapse or overt frank psychosis. Instead, therapeutic efforts should focus on mitigating secondary distress, stabilizing depressive symptoms, and bolstering adaptive coping strategies. Additionally, engaging families through psychoeducation builds a supportive home environment that fosters emotional resilience. By maintaining vigilant yet developmentally sensitive clinical monitoring, multidisciplinary teams can safeguard adolescent mental health while avoiding unnecessary pharmacological overreach.
Clinical high risk psychosis designates a state where young individuals experience subthreshold psychotic symptoms, including mild perceptual distortions or unusual beliefs. Although these individuals retain reality testing, they face elevated vulnerability to mental health disorders and functional impairment, necessitating proactive clinical observation, specialized psychotherapeutic care, and comprehensive developmental monitoring.
Older adolescent females frequently experience elevated baseline depression, peer stressors, and normative developmental psychosis-like experiences that persist over time. Consequently, their symptoms often reflect enduring emotional distress rather than imminent progression to schizophrenia. This persistent distress delays clinical remission on standard psychometric rating scales without necessarily increasing full psychotic conversion.
International guidelines do not recommend routine antipsychotic therapy for youth at clinical high risk due to adverse metabolic and neurological effects. Instead, clinicians prioritize evidence-based psychological interventions, including cognitive-behavioral therapy and family psychoeducation. Physicians reserve antipsychotics exclusively for severe, progressive functional decline or emerging full-threshold psychotic episodes under expert psychiatric supervision.
Disclaimer: This content is for informational and educational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A naturalistic study reveals how sex and age interact in children and adolescents at clinical high risk for psychosis. While core psychotic risk symptoms do not differ significantly between sexes, older adolescent females experience lower remission rates, underscoring the need for tailored developmental assessment.
Today

A Bayesian component network meta-analysis of 130 RCTs reveals that self-monitoring and gamification provide the clearest positive effects in mHealth physical activity interventions, while social comparison may have adverse psychological trade-offs.
Today

The GESS-AEEM consensus establishes a clear clinical implementation framework for testosterone therapy in postmenopausal women with hypoactive sexual desire disorder, focusing on transdermal dosing, precise laboratory monitoring, and safety communication.
Today

A multicenter observational study evaluated an 8-week digital health monitoring platform using wearable sensors in ambulatory heart failure. While participants achieved high daily wear-time of 11.7 hours and 80% completion, initial recruitment revealed significant technology-related onboarding barriers.
Today

A paired cadaveric study compared triple and quintuple percutaneous Achilles tendon lengthening. While quintuple hemisection showed numerically greater elongation, differences were not statistically significant.
Yesterday

A clinical decision-support framework using health checkup data from 231,683 adults predicts incident obesity with high discrimination (AUROC 0.918). The system integrates temporal survival analysis and risk-factor explanations to prioritize individualized preventive interventions.
Today